secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2023-09-19T23:59:59+00:00
Accession:  0000950170-23-048785
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara Therapeutics enters into $2.85M ATM sales agreement with A.G.P.
-----------------------------------------------------------------------

- Up to $2.85M of common stock may be offered and sold from time to time via Agent A.G.P./Alliance Global Partners.
- Agent receives 3.0% commission on gross proceeds; Company reimburses up to $50,000 in initial expenses.
- Initially reserved 685,096 shares based on $4.16 closing price on Sep 15, 2023.
- Sales may be made on Nasdaq Capital Market as 'at-the-market' under Rule 415; Company not obligated to sell.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023048785/0000950170-23-048785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023048785/ktra-20230919.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-048785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer